Antibody therapy of cancer

被引：1655
作者：
Scott, Andrew M. [1 ,2 ]
Wolchok, Jedd D. [3 ,4 ,5 ,6 ]
Old, Lloyd J. [4 ,5 ,6 ]
机构：
[1] Univ Melbourne, Ludwig Inst Canc Res, Melbourne, Vic 3084, Australia
[2] Austin Hosp, Ctr PET, Melbourne, Vic 3084, Australia
[3] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA
[4] Mem Sloan Kettering Canc Ctr, Ludwig Inst Canc Res, New York, NY 10065 USA
[5] Mem Sloan Kettering Canc Ctr, Ludwig Ctr Canc Immunotherapy, New York, NY 10065 USA
[6] Weill Cornell Med Coll, New York, NY 10065 USA
来源：
NATURE REVIEWS CANCER | 2012年 / 12卷 / 04期
基金：
英国医学研究理事会;
关键词：
METASTATIC COLORECTAL-CANCER; C-RECEPTOR POLYMORPHISMS; GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODY; PHASE-I; BREAST-CANCER; NEXT-GENERATION; KRAS MUTATIONS; DRUG-THERAPY; TRIAL;
D O I：
10.1038/nrc3236
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The use of monoclonal antibodies (mAbs) for cancer therapy has achieved considerable success in recent years. Antibody-drug conjugates are powerful new treatment options for lymphomas and solid tumours, and immunomodulatory antibodies have also recently achieved remarkable clinical success. The development of therapeutic antibodies requires a deep understanding of cancer serology, protein-engineering techniques, mechanisms of action and resistance, and the interplay between the immune system and cancer cells. This Review outlines the fundamental strategies that are required to develop antibody therapies for cancer patients through iterative approaches to target and antibody selection, extending from preclinical studies to human trials.
引用
收藏
页码：278 / 287
页数：10
相关论文
共 55 条
[11]   Therapeutic antibodies for autoimmunity and inflammation [J].
Chan, Andrew C. ;
Carter, Paul J. .
NATURE REVIEWS IMMUNOLOGY, 2010, 10 (05) :301-316
[12]   Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer [J].
Chen, SL ;
Yu, LK ;
Jiang, CY ;
Zhao, Y ;
Sun, D ;
Li, SY ;
Liao, GQ ;
Chen, YC ;
Fu, Q ;
Tao, Q ;
Ye, D ;
Hu, PS ;
Khawli, LA ;
Taylor, CR ;
Epstein, AL ;
Ju, DW .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (07) :1538-1547
[13]   Drug therapy: Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma [J].
Cheson, Bruce D. ;
Leonard, John P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (06) :613-626
[14]   Translating cancer research into targeted therapeutics [J].
de Bono, J. S. ;
Ashworth, Alan .
NATURE, 2010, 467 (7315) :543-549
[15]   Current Constructs and Targets in Clinical Development for Antibody-Based Cancer Therapy [J].
Deckert, P. M. .
CURRENT DRUG TARGETS, 2009, 10 (02) :158-175
[16]   Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer [J].
Dijkers, E. C. ;
Munnink, T. H. Oude ;
Kosterink, J. G. ;
Brouwers, A. H. ;
Jager, P. L. ;
de Jong, J. R. ;
van Dongen, G. A. ;
Schroder, C. P. ;
Lub-de Hooge, M. N. ;
de Vries, E. G. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (05) :586-592
[17]   PHASE-I AND IMAGING TRIAL OF INDIUM-111-LABELED ANTIEPIDERMAL GROWTH-FACTOR RECEPTOR MONOCLONAL-ANTIBODY 225 IN PATIENTS WITH SQUAMOUS-CELL LUNG-CARCINOMA [J].
DIVGI, CR ;
WELT, S ;
KRIS, M ;
REAL, FX ;
YEH, SDJ ;
GRALLA, R ;
MERCHANT, B ;
SCHWEIGHART, S ;
UNGER, M ;
LARSON, SM ;
MENDELSOHN, J .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (02) :97-104
[18]   VEGF-targeted therapy: mechanisms of anti-tumour activity [J].
Ellis, Lee M. ;
Hicklin, Daniel J. .
NATURE REVIEWS CANCER, 2008, 8 (08) :579-591
[19]   Tumor Antigen-Targeted, Monoclonal Antibody-Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape [J].
Ferris, Robert L. ;
Jaffee, Elizabeth M. ;
Ferrone, Soldano .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (28) :4390-4399
[20]   Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-1 and receptor-2 agonists for cancer therapy [J].
Fox, Norma Lynn ;
Humphreys, Robin ;
Luster, Troy A. ;
Klein, Jerry ;
Gallant, Gilles .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (01) :1-18
123456